

Medical drug benefit *Clinical Criteria* updates

On June 18, 2020, August 21, 2020, and November 20, 2020, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Anthem Blue Cross. These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. If you have questions or would like additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
May 18, 2021	ING-CC-0183*	Sogroya (somapacitan-beco)	New
May 18, 2021	ING-CC-0148*	Agents for Hemophilia B	Revised
May 18, 2021	ING-CC-0149*	Select Clotting Agents for Bleeding Disorders	Revised
May 18, 2021	ING-CC-0065	Agents for Hemophilia A and von Willebrand Disease	Revised
May 18, 2021	ING-CC-0125	Opdivo (nivolumab)	Revised
May 18, 2021	ING-CC-0119	Yervoy (ipilimumab)	Revised
May 18, 2021	ING-CC-0121*	Gazyva (obinutuzumab)	Revised
May 18, 2021	ING-CC-0048 *	Spinraza (nusinersen)	Revised
May 18, 2021	ING-CC-0002*	Colony Stimulating Factor Agents	Revised
May 18, 2021	ING-CC-0034*	Hereditary Angioedema Agents	Revised
May 18, 2021	ING-CC-0041*	Complement Inhibitors	Revised
May 18, 2021	ING-CC-0071*	Entyvio (vedolizumab)	Revised
May 18, 2021	ING-CC-0064*	Interleukin-1 Inhibitors	Revised
May 18, 2021	ING-CC-0042*	Monoclonal Antibodies to Interleukin-17	Revised
May 18, 2021	*ING-CC-0066*	Monoclonal Antibodies to Interleukin-6	Revised
May 18, 2021	ING-CC-0050*	Monoclonal Antibodies to Interleukin-23	Revised
May 18, 2021	ING-CC-0078*	Orencia (abatacept)	Revised
May 18, 2021	ING-CC-0063*	Stelara (ustekinumab)	Revised

<https://providers.anthem.com/ca>

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County.

ACA-NU-0312-21 February 2021

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
May 18, 2021	ING-CC-0062*	Tumor Necrosis Factor Antagonists	Revised
May 18, 2021	ING-CC-0003*	Immunoglobulins	Revised
May 18, 2021	ING-CC-0039*	GamaSTAN (immune globulin [human])	Revised
May 18, 2021	ING-CC-0053	Injectable Hydroxyprogesterone for Prevention of Preterm Birth	Revised
May 18, 2021	ING-CC-0073*	Alpha-1 Proteinase Inhibitor Therapy	Revised
May 18, 2021	ING-CC-0075	Rituximab Agents for Non-Oncologic Indications	Revised
May 18, 2021	ING-CC-0072	Selective Vascular Endothelial Growth Factor (VEGF) Antagonists	Revised
May 18, 2021	ING-CC-0166*	Trastuzumab Agents Step Therapy	Revised
May 18, 2021	ING-CC-0167*	Rituximab Agents for Oncologic Indications Step Therapy	Revised
May 18, 2021	ING-CC-0107*	Bevacizumab for Non-Ophthalmologic Indications	Revised
May 18, 2021	ING-CC-0027*	Denosumab Agents	Revised
May 18, 2021	ING-CC-0019*	Zoledronic Acid Agents (Reclast, Zometa)	Revised
May 18, 2021	ING-CC-0011*	Ocrevus (ocrelizumab)	Revised
May 18, 2021	ING-CC-0174*	Kesimpta (ofatumumab)	Revised